Advances on genotoxic impurities of sulfonate esters in pharmaceuticals

doi:10.3724/SP.J.1123.2018.05004

Abstract

Abstract:

This article reviews the refinement of regulatory guidelines and progress of research on the control of genotoxic impurities in pharmaceuticals in the last decade. It outlines advances in the regulatory requirements for genotoxic impurities from strict avoidance to the currently accepted concept of threshold of toxicological concern (TTC), which is based on risk control considerations. Specific control limits, which are required by predominant administrative regulatory agencies, such as U. S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH), etc. Sulfonate esters, an important class of potential genotoxic impurities, are usually generated by side-reactions between sulfonic acids or their derivatives and relative low molecular mass alcohols, such as methanol, ethanol, and isopropanol. The resulting sulfonate esters are characterized with diverse chemical structures. Reaction mechanisms of the formation of sulfonate esters and various strategies to control them have been schematically described. A detailed summary has been given for the analytical methodology developed using high performance liquid chromatography (HPLC) and gas chromatography (GC) to determine trace amounts of sulfonate esters in pharmaceuticals. Furthermore, we have comprehensively discussed the options for the chromatographic methods, sample pretreatments, and derivatization methods, as well as each method's sensitivity and recovery at trace level. This review intended to provide constructive suggestions for the rational control of sulfonate esters in pharmaceuticals to ensure their clinical safety.

Key words: chromatographic method, control strategy, genotoxic impurity, review, sulfonate ester

CLC Number:

O658

LIU Xuewei, LI Cheng, HAN Haiyun, ZHANG Wenpeng, CHEN Dongying. Advances on genotoxic impurities of sulfonate esters in pharmaceuticals[J]. Chinese Journal of Chromatography, 2018, 36(10): 952-961.

References

[1] Mcgovern T, Jacobson-kram D. TrAC-Trends Anal Chem, 2006, 25(8):790
[2] Greene N, Dobo K L, Kenyon M O, et al. Regul Toxicol Pharmacol, 2015, 72(2):335
[3] Reddy A V B, Jaafar J, Umar K, et al. J Pharm Biomed Anal, 2015, 38(5):764
[4] Teasdale A, Elder D P. TrAC-Trends Anal Chem, 2018, 101:66
[5] European Medicines Agency. Annual Report of the European Agency for the Evaluation of Medicinal Products. (2002-12-18)[2018-05-01].http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500016741&mid=WC0b01ac058009a3dc
[6] European Medicines Agency. Guideline on the Limits of Genotoxic Impurities. (2006-06-28)[2018-05-01]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500002903&mid=WC0b01ac058009a3dc
[7] Müller L, Mauthe R J, Riley C M, et al. Regul Toxicol Pharmacol, 2006, 44(3):198
[8] Ma L, Ma Y N, Chen Z, et al. Chinese Journal of New Drugs, 2014, 23(18):2106 马磊, 马玉楠, 陈震, 等. 中国新药杂志, 2014, 23(18):2106
[9] Galloway S M, Reddy M V, McGettigan K, et al. Regul Toxicol Pharmacol, 2013, 66(3):326
[10] European Medicines Agency. Question & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities. (2010-01-14)[2018-05-01]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500002907&mid=WC0b01ac058009a3dc
[11] U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Genotoxic and Carcinogenic Impurities in Drug Substances and Products:Recommended Approaches.[2018-05-01]. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm528107.html
[12] The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). M7 (R1):Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic.[2018-05-01]. http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html
[13] Elder D P, Delaney E D, Teasdale A, et al. J Sep Sci, 2010, 99(7):2948
[14] Thomson Reuters Integrity.[2018-02-07]. https://integrity.thomson-pharma.com/integrity/xmlxsl
[15] European Directorate for the Quality of Medicines and Healthcare. Pharmeuropa.[2018-05-01]. http://pharmeuropa. edqm.eu/PharmeuropaArchives
[16] Müller L, Gocke E, Lavé T, et al. Toxicol Lett, 2009, 190(3):317
[17] Szekely G, Amores de Sousa M C, Gil M, et al. Chem Rev, 2015, 115(16):8182
[18] Glowienke S, Frieauff W, Allmendinger T, et al. Mutat Res Genet Toxicol Environ Mutagen, 2005, 581(1):23
[19] U. S. National Library of Medicine, National Institutes of Health, Chemical Carcinogenesis Research Information System (CCRIS).[2018-02-22]. https://toxnet.nlm.nih.gov/newtoxnet/ccris.htm
[20] Teasdale A, Eyley S C, Delaney E, et al. Org Process Res Dev, 2009, 13(3):429
[21] Teasdale A, Delaney E J, Eyley S C, et al. Org Process Res Dev, 2010, 14(4):999
[22] Snodin D, Teasdale A. Org Process Res Dev, 2015, 19(11):1465
[23] Zheng F, Hua G D. Chinese Journal of Modern Applied Pharmacy, 2017, 34(3):396 郑飞, 华国栋. 中国现代应用药学, 2017, 34(3):396
[24] Taylor G E, Gosling M, Pearce A. J Chromatogr A, 2006, 1119:231
[25] Zhang W, Chen Y H, Zheng F. Chinese Journal of Pharmaceuticals, 2015, 46(12):1334 张薇, 陈夷花, 郑枫. 中国医药工业杂志, 2015, 46(12):1334
[26] Qian J Q, Zhang Y F, Wang J, et al. Chinese Journal of Pharmaceutical Analysis, 2017, 37(11):1994 钱建钦, 张云峰, 王建, 等. 药物分析杂志, 2017, 37(11):1994
[27] Kakadiya P R, Reddy B P, Singh V, et al. J Pharm Biomed Anal, 2011, 55(2):379
[28] Chen C, Yin L, Wang Y, et al. Journal of Shenyang Pharmaceutical University, 2015, 32(9):695 陈成, 尹璐, 王媛, 等. 沈阳药科大学学报, 2015, 32(9):695
[29] Guo T, Shi Y Y, Zheng L, et al. J Chromatogr A, 2014, 1355:73
[30] Cappiello A, Famiglini G, Palma P, et al. J Chromatogr A, 2012, 1255:286
[31] An J G, Sun M J, Bai L, et al. J Pharm Biomed Anal, 2008, 48(3):1006
[32] Zhou J, Xu J, Zheng X Y, et al. J Sep Sci, 2017, 40:3414
[33] Li W Y. J Chromatogr A, 2004, 1046:297
[34] Zheng F, Hua G D. Journal of International Pharmaceutical Research, 2016, 43(3):575 郑飞, 华国栋. 国际药学研究杂志, 2016, 43(3):575
[35] Ramakrishna K, Raman N, Rao K M V N, et al. J Pharm Biomed Anal, 2008, 46(4):780
[36] Zhang C, Huang L, Wu Z, et al. J Sep Sci, 2016, 39(18):3558
[37] Colón I, Richoll S M. J Pharm Biomed Anal, 2005, 39(3/4):477
[38] Wollein U, Schramek N. Eur J Pharm Sci, 2012, 45(1/2):201
[39] Lee C R, Guivarch F, Van Dau C N, et al. Analyst, 2003, 128(7):857
[40] Alzaga R, Ryan R W, Taylor-Worth K, et al. J Pharm Biomed Anal, 2007, 45(3):472
[41] European Pharmacopoeia Commission. European Pharmacopoeia, 9th ed. Council of Europe, Strasbourg:2017
[42] Fan D, Tu J S. Progress in Pharmaceutical Sciences, 2014, 38(3):220 范达, 涂家生. 药学进展, 2014, 38(3):220
[43] Liu X W, Zhang W P, Chen D Y, J Pharm Biomed Anal, 2018, 155:104